Skip to main content
Clinical Trials/NCT01185145
NCT01185145
Unknown
Phase 2

A Phase II Study of Accelerated Partial Breast Radiotherapy With Either a Novel Breast Brachytherapy Technique - Mammosite or Intensity Modulated Radiotherapy

Rocky Mountain Cancer Centers6 sites in 1 country291 target enrollmentFebruary 2004
ConditionsBreast Cancer

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Breast Cancer
Sponsor
Rocky Mountain Cancer Centers
Enrollment
291
Locations
6
Primary Endpoint
Overall Survival
Last Updated
12 years ago

Overview

Brief Summary

Accelerated Partial Breast Irradiation by Mammosite and intensity modulated radiotherapy is safe and effective in patients with early stage breast cancer resected by lumpectomy.

Registry
clinicaltrials.gov
Start Date
February 2004
End Date
August 2024
Last Updated
12 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Be a Tis, T1, N0, M0 AJC Classification
  • Have negative surgical margins (\> or = 2 mm) after final surgery
  • Should have adequate skin spacing between balloon surface and surface the skin (\> 7 mm)\*
  • Patients with infiltrating lobular histologies should have breast MRI scanning as part of the initial staging to verify localized T1, or Tis disease
  • Multifocal findings (define as 2 or more breast quadrants) on MRI scanning should be further evaluated by ultrasound and, if necessary biopsy, to exclude multiquadrant disease.

Exclusion Criteria

  • Be pregnant or breast-feeding
  • Have collagen-vascular disease
  • Inadequate surgical margins (\< 2 mm)
  • Patients with malignant/suspicious calcifications

Outcomes

Primary Outcomes

Overall Survival

Time Frame: 2-15 years

Ipsilateral breast failure

Time Frame: 2-15 years

Disease free survival

Time Frame: 2-15 years

Cause specific survival

Time Frame: 2-15 years

Secondary Outcomes

  • Serious Adverse device-related Events(2-5 years)

Study Sites (6)

Loading locations...

Similar Trials